University of Michigan Medical School
|
|
Hematology-Oncology |
| Ann Arbor VA Medical
Center and University of Michigan Medical School |
|
|||
|
This resource provides access to materials protected by United States and/or international copyright law. It is intended to facilitate "fair use" by those with legitamate access to these works. Learn more about copyright and fair use. |
|||
Site-Specific Resources |
NCI
Guidance  |
|
| NCCN Guidelines | ||
| Site | Treatment | Regimen | Links | Citation | Order Template | ||
| Head and Neck | |
||||||
| larynx | |
||||||
| organ preservation | chemo/RT | VA larynx | Abs | VALCSG 91 NEJM 324:1685 |
|||
| Forastiere | Abs | Forastiere 03 NEJM 349:2091 |
forastiere-larynx | ||||
| Brizel | Abs | Brizel
98 NEJM 338:1798 |
brizel | ||||
| Denis | Abs | Denis 04 JCO 22:69 |
|||||
| hypopharynx | |
||||||
| chemo/RT | Lefebvre/EORTC | Abs | Lefebvre
96 JNCI 88:890 |
||||
| Brizel | Abs | Brizel
98 NEJM 338:1798 |
brizel | ||||
| nasopharynx | |
||||||
| chemo+RT | Al-Sarraf/Int0099 | Abs | Al-Sarraf 98 JCO 16:1310 |
al-sarraf | |||
| multiple | |||||||
| chemo+RT | Brizel | Abs | Brizel
98 NEJM 338:1798 |
brizel | |||
| chemo+RT | Adelstein 2000 | Abs | Adelstein
00 |
||||
| chemo+RT | Adelstein 2002 | Abs | Adelstein 02 JCO 20:1405 |
||||
| chemo+RT | Adelstein 2003 | Abs | cisrad | ||||
| post-op | chemo+RT | Cooper 2004 | Abs | cisrad | |||
| recurrent | FU+cisplat | Jacobs | Abs | Jacobs
92 J Clin Oncol 10:257 |
|||
| FU+carbo | |||||||
| Taxol+cisplat | Adamo | Abs | Adamo 04 Oral Onc 40:525 |
||||
| Lung | |
||||||
| Small Cell | |
||||||
| chemo+RT (bid vs qd) | Turrisi 1999 | Abs | Turrissi | cisplatvp1 | |||
| cisplat+vp dose resp. | Ihde 1994 | Abs | Ihde
94 J Clin Oncol 12:2022 |
cis-vp | |||
| carbo+vp | Skarlos 2001 | Abs | carbo-vp | ||||
| Irino+cis vs cis+VP16 | Noda | Abs | Noda 02 NEJM 346:85 |
||||
| NSCLC | |
||||||
| chemo/RT review | Ruff | Ruff 03 Onc SE 1:18 |
|||||
| NSC, III | chemo/RT | ||||||
| carbo+taxol+RT | Socinski/UNC | Abs | Socinski
00 Cancer 89:534 |
unc-chemo-rt | |||
| Rosenman/UNC | Abs | Rosenman 02 IJROBP 54:348 |
unc-chemo-rt | ||||
| chemo+RT | Sause | Sauce
00 Chest 117:358 |
|||||
| metaanalysis | Pritchard 1996 | Abs | Pritchard
96 Ann Int Med 125:723 |
||||
| NSC, IV | General Approach | Ruff | Ruff 03 Onc SE 1:18 |
||||
| carbo+taxol (7/175) | Kosmidis 1997 | Abs | Kosmidis 00 Ann Onc 11:799 |
carbo-tax7_175 beta | |||
| carbo+taxol (6/200) | Kosmidis 2002 | Abs | Kosmidis 02 JCO 20:3578 |
carbo-tax6_200 | |||
| gem+cisplat | Scagliotti 2002 | Abs | Scagliotti
02 JCO 20:4285 OS Curve |
||||
| gem+cisplat | Abratt 1997 | Abs | gen-cis-abratt | ||||
| gemzar+taxol(1000/200) | Kosmidis 2002 | Abs | Kosmidis 02 JCO 20:3578 |
gem-tax | |||
| platinum regimens RCT | Scagliotti 2002 | Abs | Scagliotti
02 JCO 20:4285 OS Curve |
||||
| docetaxel+carboplatin | Millward 2003 | Abs | doce-carbo | ||||
| docetaxel+gemcitabine | Niho 2003 | Abs | doce-gem | ||||
| Iressa | FDA | ||||||
| Public Citizen | |||||||
| Evaluation | PET-CT | Bradley 2004 | Bradley 04 IJROBP 59:78 |
||||
| PET editorial | Paulino 2004 | Paulino 2004 IJROBP 59:4 |
|||||
| PET in Oncology | Czernin 2002 | Czernin 2002 Acta Med Austriaca 29:162 |
|||||
| Esophagus | |
||||||
| EUS Staging | Rice 2003 | Rice 2003 JTCV Surg 125:1091 |
|||||
| TFC->FC+XRT->Surgery | Swisher 2003 | Swisher 2003 IJROBP 57:120 |
|||||
| Pre-Op CisplatFU+RT | Kleinberg 2003 | Kleinberg 2003 IJROBP 56:328 |
|||||
| Meta-analysis | Urschel 2003 |
Urschel 2003 AJ Surg 185:538 |
|||||
| Celiac Axis Node Issues | Frizzell 2003 | Frizzell 2003 AJCO 26:215 |
|||||
| Pre-Op Chemo (no RT) | Kelsen 1998 | Kelsen 98 NEJM 339:1979 |
|||||
| Pre-Op Rx of Adeno Ca | Walsh 1996 | Walsh 96 NEJM 335:462 |
|||||
| Walsh f/u correspondence | (various) 1997 | various 97 NEJM 336:374 |
|||||
| unresectable | Cooper
1999 (Herskovic) |
Abs | Cooper
99 JAMA 281:1623 correspondence |
herskovic | |||
| rec/metastatic | |||||||
| Stomach/GE Junction | |
||||||
| adjuvant | MacDonald | Abs | MacDonald
01 NEJM 345:725 |
gastric-adj | |||
| metastatic | Taxol+5FU | Murad | |||||
| Pancreas | |
||||||
| adjuvant | RT + 5FU PVI | Mehta | Abs | fu-sens-rt | |||
| Whittington | Abs | fu-sens-rt | |||||
| Osti | Abs | ||||||
| rec/metastatic | gemcitabine | Burris | Abs | ||||
| gemcitabine+capecitabine | Hess | Abs | Hess 03 JCO 21:66 |
gem-cap | |||
| gemcitabine+cisplat | Phillip | Abs | Philip 01 Cancer 92:569 |
gem-cis | |||
| Liver, Bile Ducts | Liver | |
|||||
| Bile Duct | |||||||
| confined | sensFU+RT | Whittington | Abs | ||||
| transplantation | Yoo | Yoo
03 JCO 21:4329 |
|||||
| Colon | |
||||||
| adjuvant | FL+Oxaliplatin | Andre | Andre 04 NIJM 350:2343 |
||||
| 5-FU+Levamisole, 12 month | Moertel 1995 | Abs | |||||
| 5-FU+Leuc, qDx5, 6 month | O'Connell 1997 | Abs | fuleuc-dx5-adj | ||||
| 5-FU+ Leuc, weekly | Wolmark 1993 |
Abs | fuleuc-wk-adj | ||||
| Leucovorin 20 vs 500/M2 | Jager 1996 | Abs | |||||
| Clinical Announcement 1991 | NCI | ||||||
| liver exclusive | ablation | links | |||||
| distant mets | Review | Coco 03 Onc SE CME 1:92 |
|||||
| D'Entremont 03 Onc SE 6:155 |
|||||||
| 5-FU+Leuc, qDx5 | Poon 1989 | Abs | fuleuc-dx5-met | ||||
| 5-FU+ Leuc, weekly | Jager 1996 | Abs | fuleuc-wk-met | ||||
| FU PVI | Hanson | Hansen-96 JNCI 88:668 |
|||||
| Irinotecan | Rothenberg | Rothenberg
99 Cancer 85:786 |
irino-6wk | ||||
| Irinotecan | Pitot 1997 | Abs | Pitot 97 jco 15:2910 |
irino-6wk | |||
| Irinotecan | Ulrich-Pur 2001 | Abs | Ulrich-Pur
01 Ann Oncol 12:1269 |
irino-3wk | |||
| FU+Leuc+Irino | Saltz | Abs | Saltz
00 NEJM 343:905 |
irino-fuleuc-irl-saltz | |||
| FOLFOX4 | Rothenberg | Abs | Rothenberg 2003 JCO 21:2059 |
folfox4 | |||
| Oxaliplatin toxicity mgmt | Pederiva 2004 | Abs | ASCO 04 abstract 282 |
folfox4, capox-4wk | |||
| Gamelin 2004 | Abs | Gamelin 04 Clin Ca Res 10:4055 |
folfox4, capox-4wk | ||||
| CapOx, dose-intense | Scheithauer 2003 | Abs | capox-4wk | ||||
| Capecitabine+Oxaliplatin | Twelves | Twelves
02 Onc 16 (12 Sup):22 |
|||||
| Avastin+5FU+Leuc (FLA) | Kabbinavar | Abs | Kabbinavar 03 JCO 21:60 |
fuleuc-wk-met avastin |
|||
| Avastin+Saltz (IFLA) | Genentech info | avastin | |||||
| Avastin+Saltz (IFLA) | Hurwitz | Abs | Hurwitz 04 NEJM 350:2335 |
irino-fuleu-ifl-saltz avastin |
|||
| Capecitabine vs 5-FU | Cutsem | Cutsem 04 BJCa 90:1190 |
|||||
| Rectal | |
||||||
| adjuvant | O'Connell 1994 | Abs | O'Connell
94 NEJM 331:502 |
rectal-adj | |||
| Clinical Announcement 1991 | NCI | ||||||
| neoadjuvant | capecitabine/leucovorin + RT | Kim | Kim 02 IJROBP 54(2):403 |
||||
| XELOX-RT | Rodel | Rodel 03 JCO 21:3098 |
|||||
| metastatic | see colon above | ||||||
| Anal | |
||||||
| definitive | Flam 1996 | Abs | Flam
96 JCO 14:2527 |
flam-anal | |||
| Kidney | |
||||||
| Bladder | |
||||||
| MVAC | Loehrer | ||||||
| Gem+Cis | Kaufman 2000 | Abs | Kaufman
00 J Clin Oncol 18:1921 |
gem-cis-kaufman | |||
| Gem+Cis | Moore | Moore
99 JCO 17:2876 |
gem-cis-moore | ||||
| Gem+Cis vs MVAC | von der Maase | von
der Maase 00 JCO 17:3068 |
|||||
| Prostate | |
||||||
| localized | |||||||
| D1 | |||||||
| PSA Failure | definition | ASTRO 2003 | Web | CancerConsultants.com | |||
| D2 | hormonal | Samson | zoladex | ||||
| ASCO 2004 | Web | CancerConsultants.com | |||||
| Docetaxel+Prednisone | Eisenberger 2004 | Abs | Eisenberger 04 ASCO abstract No.4 |
doce-pred |
|||
| Mitoxantrone+Prednisone | Tannock 1996 | Abs | Tannock 96 JCO 4:1756 |
mitoxan-pred |
|||
| D3 | emcyt+VP | Pienta | Abs | Pienta
97 Urology 50:401 |
|||
| D3 | Taxane-based | Saverese | |||||
| pamidronate | Small | Small
03 JCO 21:4277 |
|||||
| Testicular | |
||||||
| PEB | Loehrer 1995 | Abs | Loehrer
95 JCO 13:470 |
peb | |||
| Breast | |
||||||
| adjuvant | |||||||
| locally adv. | |||||||
| metastatic | CMF | Harper-Wayne | |||||
| CAF | Stewart | ||||||
| Her2+Taxol | Slamon | ||||||
| Her2+Taxol | Seidman | ||||||
| male | |
||||||
| GYN | |||||||
| Ovarian | |
||||||
| Epithelial | |
||||||
| Germ Low MP |
|
||||||
| Endometrial | |
||||||
| Cervical | |
||||||
| Brain | |
||||||
|
|
glioma | PCV | MRC-BTWG | MRC-BTWP
01 JCO 19:509 |
|||
| correspondence re: above | Chamberlain | Chamberlain
01 JCO 19:3997 |
|||||
| PCV | Levin | Abs | Levin 80 Ca Treat Rep 64:237 |
pcv | |||
| oligodendro | PCV | Diabira | Diabira
01 JNeuro-Onc 55:45 |
||||
| TMZ | van den Bent | van
den Bent 01 Neuro 57:340 |
|||||
| Skin | |
||||||
| Melanoma, adjuvant | IFN alpha-2b, adjuvant | Kirkwood | |||||
| Melanoma, node neg | IFN alpha-2b, IL2 adjuvant | Hauschild | |||||
| Melanoma, recurent | High Dose IL2 | Atkins | PPT | PowerPoint
presentation to National Academy of Sciences |
|||
| Sarcoma | |
||||||
| Soft Tissue | Doxorubicin+Ifosfamide | Le Cesne 2000 | Abs | Le Cesne 00 JCO 18:2676 |
dox-ifos | ||
| MAID | Antman | Antman
98 Cancer 82:1288 |
|||||
| Osteosarcoma | |
||||||
| Unknown Primary | |||||||
| TFL (vs Cisplat+VP16) | Dowell | ||||||
The Heme-Onc Resouce page is continuously revised and updated.
Please send comments and suggestions to:
